Sanofi ADR (SNY : NASDAQ)
Common Stock
$21.14
USD
-24.41 (-53.59%)
Last updated: 2026-11-03
Follow SNY
SNY
Sanofi ADR
WealthAwesomePerformance
1 Day
-0.48%
1 Week
+8.21%
1 Month
+13.55%
YTD
-0.80%
Key Statistics
Market Cap
$109.14B
52W High
$49.91
52W Low
$39.07
P/E Ratio
22.66
50 Day MA
$42.21
200 Day MA
$44.33
Beta
0.27
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/3/2026 | $45.53 | $45.70 | $45.05 | $45.33 | $45.33 | 5,630,415 |
| 11/2/2026 | $44.50 | $45.59 | $44.50 | $45.55 | $45.55 | 7,368,661 |
| 10/30/2026 | $44.82 | $45.30 | $44.23 | $44.34 | $44.34 | 15,100,900 |
| 10/29/2026 | $42.34 | $43.15 | $42.17 | $43.13 | $43.13 | 4,264,131 |
| 10/28/2026 | $41.83 | $42.33 | $41.63 | $42.24 | $42.24 | 2,909,365 |
| 10/27/2026 | $41.55 | $41.97 | $41.53 | $41.89 | $41.89 | 2,387,430 |
| 10/26/2026 | $41.76 | $41.89 | $41.45 | $41.79 | $41.79 | 2,683,566 |
| 10/23/2026 | $41.70 | $41.75 | $41.33 | $41.60 | $41.60 | 2,011,500 |
| 10/22/2026 | $41.17 | $42.11 | $41.07 | $41.96 | $41.96 | 3,458,790 |
| 10/21/2026 | $41.20 | $41.54 | $40.84 | $40.97 | $40.97 | 3,110,521 |
Analyst Price Targets
Based on 11 analysts covering SNY · as of Nov 4, 2026
Wall Street analysts forecast SNY stock price to rise 153.0% over the next 12 months.
Consensus
Buy3.91 / 5.00
Avg. Target
US$53.48
+153.0% Upside
Previously US$53.61 on Oct 19, 2026
Current Price
US$21.14
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SNY's historical volatility
30-Day Vol
26.5%
Annualized
90-Day Vol
24.0%
Annualized
Trend (90d)
+17.5%
Annualized drift
90d Mean
US$48.25
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$46.28 | US$42.24 – US$50.72 |
| 60 trading days | US$47.26 | US$41.52 – US$53.79 |
| 90 trading days | US$48.25 | US$41.18 – US$56.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Sanofi ADR
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. manufacturing facility in Germany. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Financials
- Revenue (TTM)
- $50.98B
- EBITDA
- $14.47B
- Profit Margin
- 8.19%
- ROE (TTM)
- 5.72%
- EPS (Diluted)
- 2.01
- Book Value
- 34.11
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About SNY.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| CHSN | Chanson International Holding Class A Ordinary Shares | $3.38 | +241.24% |
| RDAC | Rising Dragon Acquisition Corp. Ordinary Shares | $11.30 | +121.57% |
| MERC | Mercer International Inc | $0.21 | +68.25% |
| PARA | Parabolic Technologies, Inc. | $2.72 | +60.95% |
| KTTA | Pasithea Therapeutics Corp | $0.53 | +44.02% |
| FEED | ENvue Medical Inc. | $0.35 | +40.00% |
| IFBD | Infobird Co Ltd | $1.43 | +38.83% |
| CRMT | Americas Car-Mart Inc | $1.21 | +32.73% |
SNY.US news timeline
6 articles covering SNY.US, most recent first
LatestSNY vs ONC: which stock is the better value?
October 2026
- Sanofi Reports Positive 44-Week Duvakitug Data: What Investors Should Know
- Sanofi Wider Canadian Access: What Investors Should Know
- SNY vs ONC: which stock is the better value?
- Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
- SNY vs ONC: which stock is the better value?